Summary:
The purpose of this study is to assess the efficacy of seltorexant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with an selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) in double-blind treatment phase and to assess the long-term safety and tolerability of seltorexant as adjunctive therapy to an antidepressant in participants with major depressive disorder (MDD) in open-label treatment phase.
- Be 18 Years to 74 Years
- Have been diagnosed with Depression
- Have taken antidepressant in the past that did not work well
- Be currently taking an antidepresant medication but still have symptoms of depression
Qualified Participants May Receive:
Study related medical care and investigational medication at not cost